RNS.4 Jul 2018 17:07
Just re reading the RNS from today this made me smile - “To date, IVIX has completed Phase II clinical studies in Russia for Libicore. It now intends to complete the Russian Phase III clinical trial for Libicore in Q3 2019 and expects to have the results available by Q2 2019, following which it will seek approval for the marketing of Libicore in the Russian market”
well I guess the results should be good given the time line. Did no one check the RNS! IMO if the directors of Ovoca put the shareholders first then they should have returned cash and wound the company up, today’s diversification is just an excuse to keep drawing salary for a few more years - given the shares directors hold they can do what they want as they can vote anything through. Be cautious here and DYOR before buying.